Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes (original) (raw)

Effect of Pioglitazone on Lipid Profile in Type 2 Diabetic Patients

Muhammad Ahmad bilal

2012

View PDFchevron_right

Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects

Md. Aftab Uddin

Drug and Chemical Toxicology, 2013

View PDFchevron_right

Effects of Pioglitazone on Visceral Fat Metabolic Activity in Impaired Glucose Tolerance or Type 2 Diabetes Mellitus

Toshi Abe

The Journal of Clinical Endocrinology & Metabolism, 2013

View PDFchevron_right

Pioglitazone Treatment Enlarges Subcutaneous Adipocytes in Insulin-Resistant Patients

Fred C. G. J. Sweep

The Journal of Clinical Endocrinology & Metabolism, 2009

View PDFchevron_right

Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes

Anders Grubb

Journal of Internal Medicine, 2006

View PDFchevron_right

Pioglitazone suspension and its aftermath: A wake up call for the Indian drug regulatory authorities

Arif Saleem Hashmi

Journal of Pharmacology and Pharmacotherapeutics, 2013

View PDFchevron_right

Combined Therapy of Pioglitazone and Atorvastatin Alleviate Diabetes in Rats More Effectively than That of Mono Therapy

saiful Islam

Pharmacology & Pharmacy, 2014

View PDFchevron_right

Pioglitazone reduces monocyte activation in type 2 diabetes

Simona Giubilato, Filippo Crea

2009

View PDFchevron_right

Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats

Isabelle Leclercq

Gut, 2006

View PDFchevron_right

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study

Angel rodriguez

Cardiovascular Diabetology, 2011

View PDFchevron_right

Population Pharmacokinetics of Pioglitazone in South Indian Type-II Diabetic Patients

Devender Kodati

Asian Journal of Pharmaceutical and Clinical Research, 2014

View PDFchevron_right

Pioglitazone provides beneficial effect in metabolic syndrome rats via affecting intracellular Na+ Dyshomeostasis

Belma TURAN

Journal of Bioenergetics and Biomembranes, 2018

View PDFchevron_right

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial

Bancha Satirapoj

PLOS ONE, 2018

View PDFchevron_right

Antidiabetic Medications and Polypharmacy

Emily Peron

Clinics in Geriatric Medicine, 2015

View PDFchevron_right

Update on metabolic issues in HIV patients

esteban martinez

Current Opinion in HIV and AIDS, 2014

View PDFchevron_right

Is there an effective therapy available for non-alcoholic fatty liver disease?

Stefano Bellentani

F1000 Medicine Reports, 2009

View PDFchevron_right

New Drug Targets to Treat the Obesity

Sanjay Dabhade

International Journal of Current Research and Review, 2013

View PDFchevron_right

Evaluation of Guidelines on Diabetes Medication

Luca Monge

Annals of Internal Medicine, 2012

View PDFchevron_right

Comparative evaluation of Pioglitazone versus Voglibose on glycemic control in patients with Type 2 Diabetes Mellitus on Metformin

Mohd Faheem Mubeen

Journal of Medical Science And clinical Research, 2018

View PDFchevron_right

Alam et al 2008 Braz J Pharmacog

Prof Lutfun Nahar

View PDFchevron_right

Obesity and liver disease

Ayman Koteish

Best Practice & Research Clinical Endocrinology & Metabolism, 2002

View PDFchevron_right

Antiepileptic drugs and liver disease

Zaeem Siddiqi

Seizure, 2006

View PDFchevron_right

Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018

Marc Quirynen

Clinical Oral Implants Research, 2018

View PDFchevron_right

30ièmes Journées Franco-Belges de Pharmacochimie

Stephane BACH

Pharmaceuticals, 2016

View PDFchevron_right

Metabolic Syndrome and HIV Infection

dr abhijit swami

Journal of HIV & Retro Virus, 2016

View PDFchevron_right

Liver and Pancreatic Diseases Management

Nagy Habib

Advances in Experimental Medicine and Biology, 2006

View PDFchevron_right

Non-alcoholic fatty liver disease - the heart of the matter

Stephen Malnick

World Journal of Hepatology, 2015

View PDFchevron_right

Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis

Kung-Kai Kuo

Scientific Reports, 2017

View PDFchevron_right

Non alcoholic fatty liver disease. The new millennium pandemia

Adriana Puerta

Revista …, 2010

View PDFchevron_right

Comparisons of Rosiglitazone Versus Pioglitazone Monotherapy Introduction and Associated Health Care Utilization in Medicaid-Enrolled Patients with Type 2 Diabetes Mellitus

Roger Anderson

Clinical Therapeutics, 2007

View PDFchevron_right

Fatty acid flux and oxidation are increased by rimonabant in obese women

Ivana Sarac

Metabolism, 2012

View PDFchevron_right

New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated With Olanzapine Treatment

Theodore Stern

Psychosomatics, 1999

View PDFchevron_right

Journal of Population Therapeutics & Clinical Pharmacology

Ledi Necaj

View PDFchevron_right

Oxandrolone in the Treatment of HIV-Associated Weight Loss in Men

Shalender Bhasin

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2006

View PDFchevron_right

Understanding diabetes in patients with HIV/AIDS

Sanjay Kalra

Diabetology & Metabolic Syndrome, 2011

View PDFchevron_right